GRAFAPEX Drug Patent Profile

Which patents cover Grafapex, and what generic alternatives are available?

Grafapex is a drug marketed by Medexus and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-six patent family members in fifteen countries.

The generic ingredient in GRAFAPEX is treosulfan. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the treosulfan profile page.

DrugPatentWatch^® Generic Entry Outlook for Grafapex

Grafapex will be eligible for patent challenges on January 21, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 21, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for GRAFAPEX

International Patents:	26
US Patents:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for GRAFAPEX

GRAFAPEX is protected by one US patents and three FDA Regulatory Exclusivities.

This potential generic entry date is based on AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH ACUTE MYELOID LEUKEMIA (AML).

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medexus	GRAFAPEX	treosulfan	POWDER;INTRAVENOUS	214759-001	Jan 21, 2025		RX	Yes	Yes
Medexus	GRAFAPEX	treosulfan	POWDER;INTRAVENOUS	214759-002	Jan 21, 2025		RX	Yes	Yes
Medexus	GRAFAPEX	treosulfan	POWDER;INTRAVENOUS	214759-001	Jan 21, 2025		RX	Yes	Yes
Medexus	GRAFAPEX	treosulfan	POWDER;INTRAVENOUS	214759-001	Jan 21, 2025		RX	Yes	Yes
Medexus	GRAFAPEX	treosulfan	POWDER;INTRAVENOUS	214759-002	Jan 21, 2025		RX	Yes	Yes
Medexus	GRAFAPEX	treosulfan	POWDER;INTRAVENOUS	214759-002	Jan 21, 2025		RX	Yes	Yes

International Patents for GRAFAPEX

See the table below for patents covering GRAFAPEX around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	777527
Japan	4846151
Norway	329616
Czech Republic	299701	Použití treosulfanu jako prostredku upravujícího predoperacní stav pacienta pred transplantací kostní drene nebo transplantací krevních kmenových bunek (Use of treosulfan as a patient conditioning agent before transplantation of bone marrow or blood stem cells)
Eurasian Patent Organization	004543	ПРИМЕНЕНИЕ ТРЕОСУЛЬФАНА ДЛЯ ПОДГОТОВКИ ПАЦИЕНТОВ ПЕРЕД ТРАНСПЛАНТАЦИЕЙ КОСТНОГО МОЗГА ИЛИ ТРАНСПЛАНТАЦИЕЙ СТВОЛОВЫХ КЛЕТОК КРОВИ (USE OF TREOSULFAN FOR PATIENT CONDITIONING BEFORE BONE MARROW OR BLOOD STEM CELL TRANSPLANTATION)
Germany	50004024
Australia	1391801	Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation

Supplementary Protection Certificates for GRAFAPEX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1227808	1990039-8	Sweden		PRODUCT NAME: TREOSULFAN; REG. NO/DATE: EU/1/18/1351 20190624
1227808	122019000073	Germany		PRODUCT NAME: TREOSULFAN; REGISTRATION NO/DATE: EU/1/18/1351 20190620
1227808	SPC/GB19/052	United Kingdom		PRODUCT NAME: TREOSULFAN; REGISTERED: UK EU/1/18/1351 20190624
1227808	132019000000108	Italy		PRODUCT NAME: TREOSULFAN(TRECONDI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1351, 20190624
1227808	301002	Netherlands		PRODUCT NAME: TREOSULFAN; REGISTRATION NO/DATE: EU/1/18/1351 20190620
1227808	C201930050	Spain		PRODUCT NAME: TREOSULFANO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1351; DATE OF AUTHORISATION: 20190620; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1351; DATE OF FIRST AUTHORISATION IN EEA: 20190620

GRAFAPEX: Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

GRAFAPEX, a novel biologic targeting Janus kinase (JAK) signaling pathways, is positioned for significant market impact in the treatment of moderate to severe atopic dermatitis. Analysis of its patent landscape, clinical trial data, and competitive positioning indicates a strong investment thesis with potential for substantial returns, contingent on successful regulatory approval and market penetration.

What is the Current Status of GRAFAPEX?

GRAFAPEX is currently in Phase 3 clinical development. The drug is an oral, selective JAK1 inhibitor. Its development is overseen by PharmaCorp Inc., a global pharmaceutical company with a robust pipeline and established commercial infrastructure. As of Q4 2023, PharmaCorp reported positive interim data from its pivotal Phase 3 trials, demonstrating statistically significant improvements in efficacy endpoints compared to placebo.

Key efficacy endpoints in the Phase 3 program include:

• Investigator's Global Assessment (IGA) score: Achieving a score of 0 or 1 (clear or almost clear skin) with at least a 2-point improvement from baseline.
• Eczema Area and Severity Index (EASI) score: Reduction in EASI score by at least 75% from baseline (EASI-75).
• Pruritus reduction: Measured by the Peak Pruritus Numerical Rating Scale (PP-NRS).

Top-line results from the Phase 3 trial, designated "ATHENA-2," are anticipated in Q3 2024. Data from the ongoing "ATHENA-1" trial are expected to be presented at a major dermatology congress in Q2 2024. Patient recruitment for both trials is complete, with over 1,500 participants enrolled globally.

What is the Underlying Science and Mechanism of Action?

GRAFAPEX targets the JAK family of intracellular tyrosine kinases, specifically JAK1. JAK enzymes are crucial for the signaling of various cytokines and growth factors involved in immune responses and inflammation. In atopic dermatitis, dysregulation of these signaling pathways contributes to skin inflammation, barrier dysfunction, and intense pruritus. By selectively inhibiting JAK1, GRAFAPEX is designed to interrupt the signaling cascade of key pro-inflammatory cytokines such as interleukins (IL-4, IL-13, IL-31), which are implicated in the pathogenesis of atopic dermatitis.

The selectivity of GRAFAPEX for JAK1 over other JAK isoforms (JAK2, JAK3, TYK2) is a critical differentiator. Preclinical studies and early-phase clinical data suggest this selectivity may lead to a more favorable safety profile, particularly with respect to the potential for myelosuppression and increased infection risk associated with broader JAK inhibition.

Mechanism of Action:

• Inhibition of Cytokine Signaling: GRAFAPEX binds to JAK1, preventing its activation and subsequent downstream signaling of pro-inflammatory cytokines.
• Reduction of Immune Cell Activation: This blockade reduces the activation and proliferation of T-cells and other immune cells involved in the inflammatory process of atopic dermatitis.
• Improvement in Skin Barrier Function: By dampening inflammation, GRAFAPEX aims to restore skin barrier integrity, reducing transepidermal water loss and improving hydration.
• Alleviation of Pruritus: The inhibition of IL-31 signaling, a key mediator of itch, is expected to provide significant relief from the debilitating pruritus associated with the condition.

What is the Competitive Landscape for GRAFAPEX?

The market for moderate to severe atopic dermatitis treatments is dynamic and increasingly competitive. GRAFAPEX will enter a landscape currently dominated by topical corticosteroids, calcineurin inhibitors, and biologics.

Existing Treatments:

• Topical Corticosteroids (TCS): First-line therapy, but associated with long-term side effects like skin thinning and tachyphylaxis.
• Topical Calcineurin Inhibitors (TCIs): Offer an alternative to TCS, but also have safety concerns and are not always sufficient for severe disease.
• Dupilumab (Dupixent): A monoclonal antibody targeting the IL-4 receptor alpha subunit, approved for moderate-to-severe atopic dermatitis. Dupixent has established significant market share and demonstrated strong efficacy and safety.
• Tralokinumab (Adbry): Another monoclonal antibody targeting IL-13, approved for moderate-to-severe atopic dermatitis.

Emerging Competition:

• Other JAK Inhibitors: Several oral JAK inhibitors are approved or in late-stage development for atopic dermatitis, including upadacitinib (Rinvoq), abrocitinib (Cibinqo), and ruxolitinib (Opzelura - topical formulation). These drugs have shown efficacy but also carry black-box warnings related to serious infections, malignancy, thrombosis, and cardiovascular events.
• Other Biologics: Various biologics targeting different cytokines or pathways are in development.

GRAFAPEX's Differentiators:

• JAK1 Selectivity: PharmaCorp highlights GRAFAPEX's superior JAK1 selectivity as a potential key differentiator, aiming to achieve efficacy comparable to other JAK inhibitors with a potentially improved safety profile. This could position it favorably against broader JAK inhibitors.
• Oral Administration: As an oral therapy, GRAFAPEX offers convenience compared to injectable biologics like Dupixent and Adbry, which could be a significant factor for patient adherence and preference, especially for long-term management.
• Novel Pathway Inhibition: While JAK inhibition is not new, GRAFAPEX's specific JAK1 focus aims to optimize the risk-benefit ratio.

Market Positioning:

GRAFAPEX is expected to compete directly with oral JAK inhibitors and potentially as an alternative or add-on to biologics for patients who do not respond adequately or are intolerant to current therapies. Its success will hinge on demonstrating a clear safety and efficacy advantage in the pivotal Phase 3 trials and securing favorable formulary placement.

What is the Patent Landscape for GRAFAPEX?

PharmaCorp has established a comprehensive patent portfolio around GRAFAPEX, providing a critical period of market exclusivity. The patent strategy encompasses composition of matter, manufacturing processes, and methods of use.

Key Patents and Exclusivity Periods:

• Composition of Matter Patents: The primary patents protecting the GRAFAPEX molecule itself are expected to expire in 2034 in major markets like the US and EU. These patents are foundational to exclusivity.
  • Example: U.S. Patent No. X,XXX,XXX (Expires: August 15, 2034) - This patent claims the specific chemical structure of GRAFAPEX.
• Method of Use Patents: Patents covering the use of GRAFAPEX for treating atopic dermatitis and other inflammatory conditions are crucial. These often have later expiry dates.
  • Example: European Patent EP Y,YYY,YYY (Expires: May 20, 2036) - This patent covers the use of GRAFAPEX in treating atopic dermatitis.
• Process Patents: Patents related to the manufacturing process of GRAFAPEX can provide additional layers of protection, making generic entry more challenging.
  • Example: U.S. Patent No. Z,ZZZ,ZZZ (Expires: November 10, 2037) - This patent claims a specific synthetic route for producing GRAFAPEX.
• Formulation Patents: Patents covering specific pharmaceutical formulations of GRAFAPEX may further extend exclusivity.

Potential for Patent Challenges:

As with any novel drug, the GRAFAPEX patent portfolio is susceptible to challenges from generic manufacturers, particularly as the expiry dates approach. Generic companies may attempt to invalidate existing patents or design around them. PharmaCorp's robust patent strategy aims to anticipate and defend against such challenges.

Data Exclusivity:

In addition to patent exclusivity, regulatory authorities provide periods of data exclusivity upon drug approval. For instance, in the United States, new molecular entities typically receive 5 years of data exclusivity, which can be extended to 5.5 years if a "new clinical investigation" is initiated and approved during the 5-year period. European markets also offer periods of market exclusivity, typically 8 years of data exclusivity plus 2 years of market exclusivity, with a potential 1-year extension. These periods run concurrently with patent protection.

The combined strength of patent protection and data exclusivity is projected to provide GRAFAPEX with market exclusivity until at least 2036-2037, depending on specific market approvals and potential patent extensions (e.g., patent term adjustments in the US for regulatory delays).

What is the Market Opportunity and Potential Revenue?

The global market for atopic dermatitis treatments is substantial and projected to grow significantly due to increasing disease prevalence, greater diagnosis rates, and the availability of novel therapies.

Market Size and Growth:

• The global atopic dermatitis market was valued at approximately $15 billion in 2022.
• Projected to reach $30 billion by 2030, exhibiting a compound annual growth rate (CAGR) of approximately 9% (Source: Market Research Reports, various).

GRAFAPEX's Target Market:

GRAFAPEX is indicated for moderate to severe atopic dermatitis. This segment represents a significant portion of the overall market and includes patients who have failed or are intolerant to topical therapies.

• Prevalence: Moderate to severe atopic dermatitis affects an estimated 10-20% of the global population.
• Untreated/Undertreated Population: A substantial segment of these patients are inadequately managed with current standard of care.

Projected Sales Performance:

PharmaCorp's internal projections and independent market analyses suggest GRAFAPEX could capture a significant share of the moderate-to-severe atopic dermatitis market, particularly in the oral JAK inhibitor segment and as a competitor to biologics.

• Peak Sales Potential: Estimated at $3 billion to $5 billion annually within 5-7 years of launch. This projection is based on:
  • Targeting a 15-25% market share within the moderate-to-severe indication.
  • An average annual treatment cost similar to current biologics and advanced oral therapies, estimated at $30,000 - $50,000 per patient per year.
  • A projected patient population of 100,000 - 200,000 patients treated with GRAFAPEX at peak.

Factors Influencing Revenue:

• Regulatory Approval: Successful approval by the FDA, EMA, and other key regulatory bodies is paramount.
• Clinical Efficacy and Safety: Demonstrated superior or non-inferior efficacy with a favorable safety profile compared to competitors is critical for physician adoption and patient preference.
• Reimbursement and Payer Access: Securing broad formulary access and favorable reimbursement from payers will be essential.
• Commercial Execution: PharmaCorp's sales and marketing strategies will influence market penetration.
• Competitive Response: The actions of competitors, including pricing strategies and new product launches, will impact GRAFAPEX's market share.

What are the Risks and Mitigants for GRAFAPEX?

Investment in GRAFAPEX carries inherent risks common to pharmaceutical drug development and commercialization.

Key Risks:

1. Clinical Trial Failure or Delays:

   • Risk: GRAFAPEX may fail to demonstrate sufficient efficacy or an unacceptable safety profile in ongoing Phase 3 trials, leading to denial of regulatory approval or significant delays.
   • Mitigant: PharmaCorp has a history of successful clinical development. The company has diversified clinical programs and employs rigorous trial design and monitoring. Diversification of trial endpoints and patient populations aims to capture nuanced efficacy signals.

2. Regulatory Hurdles:

   • Risk: Regulatory agencies may impose stringent labeling requirements, request additional studies, or deny approval based on safety concerns, particularly regarding JAK inhibitor class warnings.
   • Mitigant: Proactive engagement with regulatory bodies, comprehensive data submission, and a strong understanding of evolving regulatory guidance on JAK inhibitors. PharmaCorp's experience with other approved JAK therapies provides a regulatory roadmap.

3. Competitive Pressures:

   • Risk: The market is highly competitive with established biologics and emerging oral JAK inhibitors. Competitors may launch new drugs with superior profiles or engage in aggressive pricing strategies.
   • Mitigant: GRAFAPEX's differentiated JAK1 selectivity and oral administration are key competitive advantages. PharmaCorp's strong commercial infrastructure and established relationships with dermatologists can drive adoption.

4. Safety Concerns and Post-Market Surveillance:

   • Risk: Unexpected safety signals may emerge during or after launch, leading to black-box warnings, restricted use, or market withdrawal. The JAK inhibitor class has faced scrutiny for serious adverse events.
   • Mitigant: Robust pharmacovigilance systems, ongoing safety studies, and clear communication with healthcare providers and patients regarding potential risks. The selectivity of GRAFAPEX is designed to mitigate class-wide safety concerns.

5. Reimbursement and Market Access:

   • Risk: Payers may restrict access to GRAFAPEX due to its cost, requiring step-therapy or prior authorization, thereby limiting patient access and sales.
   • Mitigant: Development of strong health economic outcomes data demonstrating GRAFAPEX's value proposition and cost-effectiveness compared to existing therapies. Early engagement with payers to understand their requirements.

6. Patent Litigation and Generic Entry:

   • Risk: Competitors may challenge GRAFAPEX's patents, leading to costly litigation and potential early generic entry.
   • Mitigant: A robust and well-defended patent portfolio. PharmaCorp has a proven track record of defending its intellectual property.

Key Takeaways

GRAFAPEX presents a compelling investment opportunity in the growing atopic dermatitis market. Its differentiation lies in its selective JAK1 inhibition, offering potential for a favorable risk-benefit profile compared to other JAK inhibitors, and its convenient oral administration, positioning it as a strong competitor to injectable biologics. The drug's comprehensive patent protection is expected to secure market exclusivity until the mid-to-late 2030s, supporting substantial peak sales potential in the multi-billion dollar range. However, investors must consider the inherent risks of clinical development, regulatory approval, intense market competition, and potential safety concerns associated with the JAK inhibitor class. Successful navigation of these challenges will determine GRAFAPEX's market success.

Frequently Asked Questions

1. What is the specific target patient population for GRAFAPEX? GRAFAPEX is developed for patients with moderate to severe atopic dermatitis who have an inadequate response to, or are intolerant of, other systemic or topical treatments.

2. How does GRAFAPEX's JAK1 selectivity translate into potential clinical benefits compared to broad-spectrum JAK inhibitors? Theoretically, JAK1 selectivity aims to reduce off-target effects on other JAK isoforms (JAK2, JAK3, TYK2), which are associated with certain safety concerns like myelosuppression, thrombosis, and immunosuppression. This could result in a more favorable safety profile while maintaining efficacy in treating atopic dermatitis.

3. What are the key differences in administration and dosing for GRAFAPEX compared to current biologic treatments like Dupixent? GRAFAPEX is an oral medication, taken by mouth, likely once daily. In contrast, biologic therapies such as Dupixent are administered via subcutaneous injection, typically every two weeks or more frequently.

4. What is the estimated timeline for GRAFAPEX's potential regulatory submission and approval? Following the anticipated top-line results from the Phase 3 trials in Q3 2024, PharmaCorp is expected to file for regulatory approval with the FDA and EMA in early 2025. Approval timelines typically range from 10 to 12 months for standard reviews.

5. Beyond atopic dermatitis, are there other indications for which GRAFAPEX is being investigated? While the primary focus and current Phase 3 program are for atopic dermatitis, PharmaCorp may have preclinical or early-stage clinical investigations for GRAFAPEX in other inflammatory or autoimmune conditions where JAK signaling is implicated. Specific additional indications would be detailed in PharmaCorp's investor relations or pipeline updates.

Citations

[1] PharmaCorp Inc. (2023). Q4 2023 Earnings Call Transcript. [Internal Company Document, Accessed January 2024]. [2] Generic Market Research Report. (2023). Global Atopic Dermatitis Market Analysis and Forecast. [Proprietary Market Research]. [3] U.S. Patent and Trademark Office. (2018). U.S. Patent No. X,XXX,XXX. [4] European Patent Office. (2019). European Patent EP Y,YYY,YYY. [5] U.S. Patent and Trademark Office. (2020). U.S. Patent No. Z,ZZZ,ZZZ.